Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPLORER: Triple Combination Therapy in Early Crohn's Disease
NCT02764762Phase 4Completed
- Sponsor
- Takeda
- Start
- Apr 2017
- Primary completion
- Sep 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of vedolizumab in Crohn's disease, sponsored by Takeda. Started Apr 2017; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02764762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02764762.